Sep. 17, 2009 (PR Newswire) -- CUPERTINO, Calif., Sept. 17 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)
-- Matt Hogan, Chief Financial Officer, will present at the UBS Global Life
Sciences Conference in New York on Wednesday, September 23rd at 10:30
a.m. Eastern Time. A live audio webcast of the presentation will be
available by accessing DURECT's homepage at http://www.durect.com
and clicking "Investor Relations." If you are unable to
participate during the live webcast, the call will be archived on
DURECT's website under Audio Archive in the "Investor
Relations" section.
-- Joe Stauffer, Chief Medical Officer and EVP-Corporate Strategy, will
deliver a talk entitled "Issues and Challenges with Clinical Drug
Development of Pain Compounds: Failure in Phase III and the Cart before
the Horse" at Arrowhead's 3rd Annual Pain Therapeutics Summit
in Summit, New Jersey on Friday, September 25th at 8:40 am Eastern Time.
About DURECT
DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.
NOTE: POSIDUR(TM), SABER(TM), ORADUR(TM), TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.
SOURCE DURECT Corporation
